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Abstract
Background: The World Health Organization recommends the screening of all people living with HIV for tuberculosis (TB)
disease, followed by TB treatment, or isoniazid preventive therapy (IPT) when TB is excluded. However, the difficulty of
reliably excluding TB disease has severely limited TB screening and IPT uptake in resource-limited settings. We conducted an
individual participant data meta-analysis of primary studies, aiming to identify a sensitive TB screening rule.
Methods and Findings: We identified 12 studies that had systematically collected sputum specimens regardless of signs or
symptoms, at least one mycobacterial culture, clinical symptoms, and HIV and TB disease status. Bivariate random-effects
meta-analysis and the hierarchical summary relative operating characteristic curves were used to evaluate the screening
performance of all combinations of variables of interest. TB disease was diagnosed in 557 (5.8%) of 9,626 people living with
HIV. The primary analysis included 8,148 people living with HIV who could be evaluated on five symptoms from nine of the
12 studies. The median age was 34 years. The best performing rule was the presence of any one of: current cough (any
duration), fever, night sweats, or weight loss. The overall sensitivity of this rule was 78.9% (95% confidence interval [CI]
58.3%–90.9%) and specificity was 49.6% (95% CI 29.2%–70.1%). Its sensitivity increased to 90.1% (95% CI 76.3%–96.2%)
among participants selected from clinical settings and to 88.0% (95% CI 76.1%–94.4%) among those who were not
previously screened for TB. Negative predictive value was 97.7% (95% CI 97.4%–98.0%) and 90.0% (95% CI 88.6%–91.3%) at
5% and 20% prevalence of TB among people living with HIV, respectively. Abnormal chest radiographic findings increased
the sensitivity of the rule by 11.7% (90.6% versus 78.9%) with a reduction of specificity by 10.7% (49.6% versus 38.9%).
Conclusions: Absence of all of current cough, fever, night sweats, and weight loss can identify a subset of people living with
HIV who have a very low probability of having TB disease. A simplified screening rule using any one of these symptoms can
be used in resource-constrained settings to identify people living with HIV in need of further diagnostic assessment for TB.
Use of this algorithm should result in earlier TB diagnosis and treatment, and should allow for substantial scale-up of IPT.
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Introduction
By the end of 2009, an estimated 33 million people were living
with HIV, the vast majority in sub-Saharan Africa and Asia.
Tuberculosis (TB) remains the most common cause of death in
people living with HIV. Compared to people without HIV, people
living with HIV have a more than 20-fold increased risk of
developing TB [1]. TB disease may occur at any stage of HIV
disease and is frequently the first recognized presentation of
underlying HIV infection [2,3]. Without antiretroviral treatment
(ART), up to 50% of people living with HIV who are diagnosed
with TB die during the 6–8 mo of TB treatment [4–6]. This risk
increases to 72%–98% among those with multi-drug (MDR) or
extensively drug-resistant (XDR) TB [7,8]. Although ART can
reduce the incidence of TB both at individual [9] and population
[10] levels, people living with HIV on ART still have higher TB
incidence rates and a higher risk of dying from TB [11]. Routine
TB screening offers the opportunity to diagnose and promptly
treat TB disease, and to identify those without TB disease who
may be eligible for TB preventive therapy [12]. The use of TB
preventive therapy can reduce TB incidence and is therefore of
considerable benefit to patients [13].
For these reasons, the World Health Organization (WHO)
recommends regular screening for active TB disease of all people
living with HIV and providing either treatment for active disease
or isoniazid preventive therapy (IPT) to mitigate TB morbidity,
mortality, and transmission [14]. However, in 2009, of the
estimated 33 million people living with HIV, only 1.7 million (5%)
were screened for TB, and about 85,000 (0.2%) were offered IPT
[15]. Currently there is no internationally accepted evidence-based
tool to screen for TB in people living with HIV. Several studies
have shown that the presenting signs and symptoms of TB in
people living with HIV are different from those in people without
HIV to diagnose TB; for example, many people living with HIV
who have culture-confirmed TB do not report having a prolonged
cough, which is one of the standard TB screening questions used
by national TB control programs globally [16]. Moreover, the
most widely available TB diagnostic tests such as smear
microscopy and chest radiography perform poorly among people
living with HIV; because most people living with HIV and TB
have either sputum acid-fast bacilli (AFB) smear negative
pulmonary or extrapulmonary TB [17].
We conducted an individual participant data meta-analysis of
published and unpublished studies to develop a simple, standard-
ized TB screening rule for resource-constrained settings that will
adequately separate patients into two groups: (1) those for whom
TB is reliably excluded, and IPT and ART, if indicated, can be
initiated; and (2) those who require further investigation for TB
disease. We describe the results of this meta-analysis and propose
an algorithm for TB screening among people living with HIV in
resource-constrained settings.
Methods
We proceeded through several steps. First, we prospectively
enumerated criteria for studies to be included in our meta-analysis.
Second, we searched for and selected studies that met these
criteria. Third, we sought primary data from investigators and
mapped individual-level data to common symptoms. Fourth, we
identified five symptoms available in most studies and, within each
study, computed the sensitivity and specificity of 23 screening rules
derived from these five symptoms. Finally, we used meta-analysis
methods to estimate the performance of all 23 rules, as well as the
association of study-level and individual-level correlates with
performance.
Inclusion of Studies
We defined studies as being eligible for inclusion in this analysis
if they met the following criteria: (1) collected sputum specimens
from people living with HIV regardless of signs or symptoms; (2)
used mycobacterial culture of at least one specimen to diagnose
TB; and (3) collected data about signs and symptoms.
Search Strategy and Selection of Studies
To identify studies eligible for the meta-analysis, we conducted a
systematic literature review of studies related to TB screening among
people living with HIV in June 2008 using PubMed and various
combinations of the following keywords: ‘‘HIV,’’ ‘‘Tuberculosis,’’
‘‘TB screening,’’ ‘‘Smear-negative TB,’’ ‘‘Sputum negative TB,’’ ‘‘TB
case finding,’’ ‘‘Intensified TB case finding,’’ ‘‘Isoniazid prevention
treatment, trial or therapy.’’ We also searched for abstracts presented
at conferences organized by the International Union Against TB and
Lung Diseases and the International AIDS Society between 2000–
2008. No language restriction was placed on the search. We reviewed
all retrieved titles and abstracts for relevance to the topic. The
reference lists of retrieved studies were also reviewed to identify
further studies that meet the eligibility criteria. In addition,
recognized experts in the field were contacted to identify studies that
were not available (e.g., unpublished) in the initial electronic search.
Studies that involve concomitant HIV testing and mycobacterial
culture on all patients are resource intensive and challenging to
implement in countries with a high burden of TB and HIV.
Therefore, we believe it is unlikely that eligible studies would have
been completed but missed by our search strategy.
We found 2,119 publications and reviewed all their abstracts.
Using the criteria above, we selected 53 for review of the full text.
Twenty-one articles included information on signs and symptoms
for TB screening in people living with HIV. A total of 14 studies
(six published and eight unpublished at the time of the search) met
the inclusion criteria of our meta-analysis (Figure 1). The
corresponding authors or principal investigators were contacted
for all 14 studies to confirm that their studies met all the eligibility
criteria. One unpublished dataset was excluded for not meeting
the inclusion criteria after verification with the principal
investigator, and another one was excluded because the investi-
gators could not submit the data within the agreed timeframe. A
total of 12 investigators (representing six published and six
unpublished studies at the time of the search) provided de-
identified individual patient data for inclusion in the primary
meta-analysis within an agreed time framework (Table 1) [18–29].
In November 2010, immediately preceding manuscript publica-
tion, we re-ran the search strategy again to look for additional
studies that were reported since the initial search and should have
been included in the meta-analysis. The search found seven
eligible studies, of which all except one [30] were included in our
meta-analysis as unpublished datasets.
Investigators for all included studies signed a data sharing and
confidentiality agreement, and agreed to a data management,
analysis, and publication plan. During design and analysis phases
of the meta-analysis, the investigators of the studies and data
managers of the included studies held multiple discussions by
email, by teleconference, and in person in Geneva, Switzerland
and Atlanta, Georgia, United States.
Data Abstraction and Management
The list of variables from the most comprehensive dataset [20]
was used to construct an initial master list of variables. All the
variables from each study included in the meta-analysis were
mapped to this master list. Principal investigators and data
managers for the 12 studies worked with the meta-analysis
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investigators to ensure accurate mapping of data from the primary
studies to the master variable list. In the end, the final dataset of
the meta-analysis included 159 variables that appeared in at least
two of the studies. We identified five symptoms common to most
studies and limited the meta-analysis to the nine studies with
substantially complete information for those five symptoms.
Case Definitions
We defined a TB patient as any person living with HIV and at
least one specimen culture positive for Mycobacterium tuberculosis
(MTB). We defined participants as having no TB if cultures were
negative for MTB and participants were judged not to have TB on
the basis of the original study definition of the investigators. We
excluded from the analysis: (1) patients who were receiving
treatment for TB (infection or disease) at enrolment; (2) patients
who were AFB smear positive, but whose culture grew non-
tuberculous mycobacteria; and (3) patients who were AFB smear
positive or scanty, but sputum culture negative.
Sources of Study Heterogeneity
All studies were reviewed to identify study-level characteristics
that could substantially impact the findings of the meta-analysis.
Two studies were conducted exclusively among gold miners
living in South Africa [21,23], a population that may not be
broadly generalizable, because of its demographics, its high
prevalence of non-TB illnesses (e.g., silicosis) that can produce
cough, and the practice of annual TB radiological screening.
Five studies [18,19,22,25,27] were conducted among individuals
drawn from a community setting through prevalence surveys,
which may lead to enrolment of patients with a different
spectrum of TB and HIV disease than would be found among
patients seeking care. Three studies [19,22,23] involved
participants who were previously screened for TB or who had
had access to routine TB screening before being enrolled into
the studies. Finally, three studies exclusively used liquid media
to culture specimens [26–28], two studies used both solid and
liquid media [18,20], and seven studies exclusively used solid
media (Table 1). Liquid media have substantially increased
sensitivity for growing MTB, particularly in patients with low
levels of TB bacilli, as would be expected in a population of
people living with HIV being screened for TB [31]. Studies that
used liquid media, therefore, would have improved ability to
classify patients correctly into those who have TB and those who
do not. We explored the impact of these factors on the
Figure 1. Search strategy and studies included in the meta-analysis (PRISMA flow diagram).
doi:10.1371/journal.pmed.1000391.g001
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performance of the screening algorithms and analyzed subsets of
the final dataset grouped according to these characteristics.
Data Analysis
We compared characteristics of patients with TB to those of
patients without TB to derive a standardized rule for TB screening
among people living with HIV. The goal of TB screening is to
divide the population of people living with HIV into two groups:
(1) those who do not have TB; and (2) those who need further
evaluation for the diagnosis of TB (i.e., TB suspects). We restricted
our analysis to clinical symptoms that could be readily assessed at
any level of the health system and that were asked about in all
studies: current cough (C), haemoptysis (H), fever (F), night sweats
(S), and weight loss (W). Using the four studies that included chest
radiography data [20,23,24,26], we also evaluated the impact of
adding abnormal chest radiography findings to the TB screening
rule. Only observations with no missing data for the symptoms of
interest were included in the analysis.
We considered ‘‘1-of-n’’ rules as candidates for screening for TB
that could best classify patients into two groups (not TB and
suspected TB) with high sensitivity [20]. The ‘‘1’’ represents the
minimum number of symptoms that must be present in an
individual to be classified as a suspected TB patient and the ‘‘n’’
represents the number of symptom(s) in a given rule. For example, a
‘‘1-of-3’’ rule could be a set of symptoms such as current cough,
fever, and weight loss, abbreviated here as CFW. An individual with
at least one symptom specified in this particular rule would be
classified as a TB suspect; an individual without any of these
symptoms would be classified as not having TB. We considered all
combinations of the five candidate symptoms except for combina-
tions that include both current cough and haemoptysis, yielding a
total of 23 candidate rules: two 1-of-4 rules (CFSW, HFSW), seven
1-of-3 rules (CFS, CFW, CSW, HFS, HFW, HSW, FSW), nine 1-
of-2 rules (CF, CS, CW,HF, HS, HW, FS, FW, SW), and five 1-of-1
rules (C, H, F, S, W) (see also Table 3.) The analysis with abnormal
chest radiographic findings (X) considered these 23 rules, each
augmented with this additional sign (e.g., CFSWX).
Other analyses have considered m-of-n rules with m.1 [20].
These rules cannot exceed the sensitivity of 1-of-n rules. Suppose
that a positive screen requires the presence of at least two
symptoms out of current cough, fever, and night sweats, the
number of true positives for this 2-of-3 rule will not be greater than
Table 1. Summary of studies included in the meta-analysis.
Reference
Study Population Characteristics (Setting, Continent, n Samples,
Culture Method Used)
Sample
Size
PLTB/PLHIVa
(%)
PLTB/PLHIV (%)
with Data on the
Five Symptoms
Ayles et al. 2009 Adults of more than 15 y of age sampled from one rural and one urban
communities in Zambia (community, sub-Saharan Africa, 1 LJ and MGIT).
8,044 43/2,253 (1.9) 41/2,145 (1.9)
Corbett et al. 2010b Random sample of adults in 46 previously enumerated neighbourhoods in the
high density suburbs of Harare, Zimbabwe (community, sub-Saharan Africa, 3 LJ).
10,079 31/1,841 (1.7) 31/1,834 (1.7)
Cain et al. 2010 PLHIV from 8 outpatient clinics in Cambodia, Thailand, and Vietnam who
were enrolled regardless of signs or symptoms suggestive of TB
(clinical, Southeast Asia, 3 MGIT and LJ).
1,748 267/1,724 (15.5) 267/1,721 (15.5)
Day et al. 2006 Employees of a gold mining company first attending the TB preventive
therapy clinic in South Africa (miners, sub-Saharan Africa, 2 LJ).
1,093 32/991 (3.2) 0/0 (–)
Corbett et al. 2007b Employees of 22 small and medium-sized enterprises in Zimbabwe
(community, sub-Saharan Africa, 3 LJ).
4,668 3/797 (0.4) 3/797 (0.4)
Lewis et al. 2009b All consenting employees of a gold mining indusry who undergo
annual medical examinations in an occupational health centre
in South Africa (miners, sub-Saharan Africa, 2 LJ).
1,955 18/560 (3.2) 18/560 (3.2)
Shah et al. 2009 All newly diagnosed HIV-positive clients of at least 18 y old from
the VCT Clinic in a large referral hospital in Addis Ababa, Ethiopia
(clinical, sub-Saharan Africa, 1 LJ).
453 27/427 (6.3) 22/357 (6.2)
Kimerling et al. 2002 PLHIV of at least 15 y of age and enrolled in an HIV home-based care
service in Phnom Penh, Cambodia (community, Southeast Asia, 1 LJ).
441 36/393 (9.2) 36/393 (9.2)
Lawn et al. 2009 PLHIV with more than 18 y of age who were referred to a
community-based ART service in South Africa
(clinical, sub-Saharan Africa, 2–4 MGIT).
235 58/226 (25.7) 57/218 (26.1)
Wood et al. 2007 Randomly sampled and consenting adults living in shacks in a high-density
residential area in South Africa (community, Sub-Saharan Africa, 4 MGIT).
174 12/163 (7.4) 0/0 (–)
Mohammed
et al. 2004
PLHIV with WHO clinical stage 3 or 4 disease referred for possible
participation in a trial of TB-preventive therapy in 3 hospital-based
adult HIV clinics in South Africa (clinical, sub-Saharan Africa, 1 BACTEC).
129 10/128 (7.8) 0/0 (–)
Chheng et al. 2008 All consenting participants of more than 19 y old who were
tested for HIV in a Voluntary Counseling Center and referred for TB
screening in Cambodia (clinical, Southeast Asia, 3 LJ).
504 20/123 (16.3) 20/123 (16.3)
Total 29,523 557/9,626 (5.8) 495/8,148 (6.1)
aThe following patients were excluded: (1) patients who were on TB treatment or prophylaxis at enrolment; (2) patients who were smear positive, but culture grew non-
tuberculosis mycobacterium (NTM); and (3) patients who were smear positive, but culture negative.
bPatients were previously screened for TB before enrolment into the study.
LJ, Lowenstein-Jensen culture medium; MGIT, Mycobacterial Growth Indicator Tube culture system; PLHIV, persons living with human immunodeficiency virus; PLTB,
persons with tuberculosis disease; VCT, voluntary counselling and testing for HIV.
doi:10.1371/journal.pmed.1000391.t001
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the number of true positives from the corresponding 1-of-3 rules.
Because our aim in this analysis was to identify the most sensitive
rule, we did not include rules of this kind in our analysis.
We applied two closely related methods for cross-study analysis
of sensitivity and specificity of these 23 candidate screening rules:
bivariate random-effects meta-analysis (BREMA) and the hierar-
chical summary relative operating characteristic (HSROC) curve
[32,33]. BREMA jointly models sensitivity and specificity while
accommodating between-study heterogeneity, and HSROC
models tradeoffs between sensitivity and specificity across study
populations. Both methods can be unified in the same model. In
addition to sensitivity and specificity, we calculated predictive
value negative and likelihood ratio negative of each candidate rule
[34]. Our goal was to identify a combination of symptoms that
Figure 2. Flow chart of study participants included in the individual patient data meta-analysis.
doi:10.1371/journal.pmed.1000391.g002
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Table 2. Characteristics of participants with and without TB for variables included in the analysis.
Characteristic All PLHIV (n=9,626)
PLHIV with Data on
the Five Symptoms (n=8,148)
No TB Disease
(n=9,069), n (%)
TB Disease
(n=557), n (%)
TB Disease
(n=7,653), n (%)
TB Disease
(n=495) n (%)
Origin of patient
Sub-Saharan Africa 7,152 (78.9) 234 (42.0) 5,739 (75.0) 172 (34.8)
Southeast Asia 1,917 (21.1) 323 (58.0) 1,914 (25.0) 323 (65.2)
Setting
Clinical 2,246 (24.8) 382 (68.5) 2,053 (26.8) 366 (73.9)
Community 5,322 (58.7) 125 (22.4) 5,058 (66.1) 111 (22.4)
Miners 1,501 (16.5) 50 (9.0) 542 (7.1) 18 (3.6)
Sex
Male 4,957 (54.7) 356 (63.9) 3,811 (49.8) 309 (62.4)
Female 4,111 (45.3) 201 (36.1) 3,841 (50.2) 186 (37.6)
Missing or not recorded 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0)
Median age (IQR), n=8,633 (7,286) 34 (27–41) 33 (28–40) 33 (27–40) 32 (28–39)
Median CD4+ count (IQR), n=3,489 (2,409) 268 (126–427) 106 (38–241) 229 (94–391) 94 (33–215)
Cough in the past 4 wk
Yes 1,439 (15.9) 303 (54.4) 1,270 (16.6) 278 (56.2)
No 1,909 (21.0) 129 (23.2) 1,067 (13.9) 110 (22.2)
Missing or not recorded 5,721 (63.1) 125 (22.4) 5,316 (69.5) 107 (21.6)
Cough lasting for 2 wk or more
Yes 957 (10.6) 197 (35.4) 848 (11.1) 177 (35.8)
No 3,093 (34.1) 288 (51.7) 2,046 (26.7) 260 (52.5)
Missing or not recorded 5,019 (55.3) 72 (12.9) 4,759 (62.2) 58 (11.7)
Haemoptysis
Yes 543 (6.0) 60 (10.8) 523 (6.8) 58 (11.7)
No 8,509 (71.4) 495 (88.9) 7,130 (93.2) 437 (88.3)
Missing or not recorded 17 (0.2) 2 (0.4) 0 (0.0) 0 (0.0)
Current cough or cough in the past 24 h
Yes 1,625 (17.9) 274 (49.2) 1,530 (20.0) 260 (52.5)
No 6,474 (71.4) 250 (44.9) 6,123 (80.0) 235 (47.5)
Missing or not recorded 970 (10.7) 33 (5.9) 0 (0.0) 0 (0.0)
Current fever or fever in the past 4 wk
Yes 1,801 (19.9) 294 (52.8) 1,669 (21.8) 280 (56.6)
No 7,002 (77.2) 246 (44.2) 5,984 (78.2) 215 (43.4)
Missing or not recorded 266 (2.9) 17 (3.0) 0 (0.0) 0 (0.0)
Current night sweats or night sweats in the past 4 wk
Yes 1,710 (18.9) 242 (43.4) 1,497 (19.6) 225 (45.4)
No 7,329 (80.8) 313 (56.2) 6,156 (80.4) 270 (54.6)
Missing or not recorded 30 (0.3) 2 (0.4) 0 (0.0) 0 (0.0)
Current weight loss or weight loss in the past 4 wk
Yes 2,434 (26.8) 333 (59.8) 2,258 (29.5) 308 (62.2)
No 6,478 (71.4) 218 (39.1) 5,395 (70.5) 187 (37.8)
Missing or not recorded 157 (1.7) 6 (1.1) 0 (0.0) 0 (0.0)
Abnormal chest radiography
Yes 581 (6.4) 271 (48.7) 294 (3.8) 239 (48.3)
No 2,900 (32.0) 151 (27.1) 2,155 (28.1) 145 (29.3)
Missing or not recorded 5,588 (61.6) 135 (24.2) 5,204 (68.0) 111 (22.4)
Abnormal chest radiography consistent with TB
Yes 377 (4.2) 227 (40.8) 261 (3.4) 209 (42.2)
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achieved the highest possible sensitivity and the lowest possible
negative likelihood ratio for ruling out TB disease (without any
predetermined cut-off points).
To further understand between-study heterogeneity and other
factors associated with the diagnostic performance of the most
sensitive rule, we analyzed several study-level predictors (setting,
prior screening of study participants, culture medium used, and
geographic region) and participant-level predictors (age, gender,
CD4 T-lymphocyte cell count [CD4], and abnormal chest
radiographic findings). Our analytic methods produced odds
ratios that reflect the magnitude of association between each factor
and the probability of correctly identifying persons with TB
(sensitivity) or without TB (specificity). For a range of TB
prevalence values, we calculated the negative predictive values at
levels of each covariate. We calculated the ratio of the number of
patients that screen positive but who actually have no TB (false
positives) and hence unnecessarily require additional TB diagnos-
tic evaluation (e.g., culture) to the number of patients that screen
positive and actually have TB (true positives), which is referred to
as the number needed to screen. We calculated this ratio for
different rules using a theoretical population of 1,000 people living
with HIV with different levels of TB prevalence. This ratio
provides proxy information similar to a marginal cost-effectiveness
analysis for different screening rules and it helps quantify how
much a health program would need to invest (as measured by
additional diagnostic tests) for every patient with TB identified
through the screening rule [35].
Each observation with a missing covariate value was omitted from
analysis of that covariate. BREMA models were fitted using SAS
procedure Glimmix (SAS 9.22, SAS Institute), and further calcula-
tions were performed in R (R 2.10.1, R Development Core Team).
Ethical Review
All data collection included in the meta-analysis was approved
by institutional ethical review boards at the respective institutions
during the original study; if necessary, principal investigators
requested additional approval from institutional review boards for
the inclusion of the primary dataset in the meta-analysis. All data
for the meta-analysis were provided completely de-identified. In
the meta-analysis dataset, investigators were not able to link case
records to individuals.
Results
Investigators provided data about 29,523 participants, of whom
10,057 were people living with HIV. The dataset included 9,626
people living with HIV who had TB screening and sputum culture
performed, of whom 8,148 could be evaluated on the five
symptoms of interest from nine of 12 studies (Figure 2).
Most patients (77% [7,386/9,626]) were from sub-Saharan
Africa; the rest were from Southeast Asian countries. The median
Characteristic All PLHIV (n=9,626)
PLHIV with Data on
the Five Symptoms (n=8,148)
No TB Disease
(n=9,069), n (%)
TB Disease
(n=557), n (%)
TB Disease
(n=7,653), n (%)
TB Disease
(n=495) n (%)
No 2,589 (28.5) 144 (25.8) 1,641 (21.4) 129 (26.1)
Missing or not recorded 6,103 (67.3) 186 (33.4) 5,751 (75.2) 157 (31.7)
Any one of current cough, fever, night sweats,
or weight loss
Yes 3,591 (39.6) 425 (76.3) 3,563 (46.6) 418 (84.4)
No 4,090 (45.1) 77 (13.8) 4,090 (53.4) 77 (15.6)
Not evaluable 1,388 (15.3) 55 (9.9) 0 (0.0) 0 (0.0)
doi:10.1371/journal.pmed.1000391.t002
Table 2. Cont.
Table 3. Diagnostic performance of 23 candidate 1-of-n rules.
Rule
Sensitivity
(95% CI)
Specificity
(95% CI)
LRN
(95% CI)
CFSW 78.9 (58.3–90.9) 49.6 (29.2–70.1) 0.426 (0.349–0.520)
HFSW 75.7 (53.9–89.2)a 52.7 (31.8–72.7) 0.461 (0.391–0.544)
CFW 74.0 (51.7–88.3)a 53.8 (32.8–73.6) 0.483 (0.416–0.561)
CSW 73.4 (51.0–88.0) 53.8 (32.8–73.5) 0.494 (0.428–0.570)
CFS 73.1 (50.6–87.9) 61.1 (39.7–79.0) 0.440 (0.382–0.506)
HFW 70.6 (47.5–86.4) 57.5 (36.2–76.4) 0.511 (0.454–0.576)
FSW 69.2 (45.9–85.6) 55.7 (34.5–75.0) 0.554 (0.497–0.617)
HSW 68.1 (44.6–85.0) 58.7 (37.3–77.2) 0.544 (0.492–0.602)
CW 65.3 (41.6–83.3) 60.3 (38.8–78.4) 0.576 (0.530–0.625)
CF 65.0 (41.3–83.1) 68.6 (47.7–83.9) 0.510 (0.470–0.553)
HFS 63.7 (39.9–82.3) 66.3 (45.2–82.4) 0.548 (0.509–0.589)
FW 63.1 (39.3–81.9) 61.4 (40.0–79.1) 0.601 (0.560–0.644)
SW 61.0 (37.2–80.5) 61.9 (40.5–79.5) 0.630 (0.594–0.669)
CS 59.7 (35.9–79.6) 69.4 (48.7–84.4) 0.581 (0.551–0.613)
HW 56.8 (33.3–77.6) 66.8 (45.7–82.8) 0.647 (0.620–0.675)
FS 56.3 (32.8–77.3) 70.1 (49.6–84.9) 0.623 (0.598–0.649)
HF 52.0 (29.2–74.1) 75.0 (55.6–87.7) 0.640 (0.620–0.660)
W 49.3 (27.0–71.9) 71.1 (50.8–85.5) 0.712 (0.693–0.733)
F 42.8 (22.2–66.3) 79.8 (62.4–90.4) 0.716 (0.695–0.738)
HS 38.9 (19.5–62.6) 78.1 (59.9–89.5) 0.782 (0.753–0.813)
C 38.5 (19.2–62.2) 81.8 (65.3–91.5) 0.753 (0.724–0.783)
S 31.4 (14.8–54.6) 82.2 (65.9–91.7) 0.835 (0.780–0.893)
H 5.9 (2.3–14.5) 94.4 (87.6–97.6) 0.996 (0.735–1.351)
Sensitivity, specificity, and likelihood ratio negative (LRN) from the bivariate
random-effects meta-analysis model. Rule is at least one of the indicated
symptoms. C, current cough; H, haemoptysis; F, fever; S, sweats; W, weight loss.
ap-Value .0.05 for the same sensitivity of the CFSW rule and the indicated rule.
All specificities are significantly different from that of the CFSW rule.
LRN, likelihood ratio negative.
doi:10.1371/journal.pmed.1000391.t003
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age was 34 y (interquartile range [IQR], 27–41 y). Of the 9,626
patients with HIV in the 12 studies, CD4 cell count information
was available for 3,489 (36%) and chest radiography information
for 3,903 (41%). The median CD4 count was 248 cells/ml (IQR,
107–409).
The overall prevalence of TB disease was 5.8% (557/9,626),
ranging across studies from 0.4% to 25.7% (Table 1). More than
half of TB patients (52% [288/557]) had sputum smear negative
pulmonary TB, whereas 39% (218/557) had sputum smear
positive pulmonary, and 5% (28/557) had exclusively extrapul-
monary TB. The anatomic site of TB was not specified in 4% (23/
557) of patients.
Table 2 summarizes the distribution of common variables, and
Table S1 summarizes how each question was actually asked in
each study. Because duration of cough was included in many
studies but was asked about in different ways, we were able to
analyze data using three different cough variables: cough in the
past 4 wk (information available for 39.3% of participants); cough
lasting for 2 wk or more (information available for 47.1%); and
cough present in the last 24 h, which is referred to as ‘‘current
cough’’ (information available for 89.6%).
We analyzed the performance of individual and combinations of
symptoms as screening rules using data from the 8,148 participants
who could be evaluated based on the five candidate symptoms.
Figure 3. Diagnostic performance of CFSW rule in the included studies. BREMA, bivariate random-effects meta-analysis; HSROC, hierarchical
summary relative operating characteristic.
doi:10.1371/journal.pmed.1000391.g003
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Table 3 shows the diagnostic performance characteristics for the
23 candidate combinations of symptoms, sorted from highest
sensitivity to lowest. The most sensitive rule was the presence of
any one of the following symptoms: current cough, fever, night
sweats, and weight loss (CFSW). The population-average sensitiv-
ity of this symptom combination was 78.9% (95% confidence
interval [CI] 58.3%–90.9%) with the negative likelihood ratio of
0.426 (95% CI 0.349–0.520), which corresponds to a postscreen-
ing reduction in the probability of TB by 15%–20% [34].
The nine included studies demonstrated significant between-
study heterogeneity on both sensitivity (p,0.001) and specificity
(p,0.001) of the rule CFSW (see also Figure 3). The bivariate
graphic shows that six studies have study-level specificities below
and three above the population average specificity. Furthermore,
this rule has the highest-ranking sensitivity in eight of the nine
included studies (Table S2). The hierarchical summary relative
operating characteristic curves (Figure S1) show slightly better
overall diagnostic performance of the rules CFS and CF, but our
application requires the highest sensitivity possible, allowing for
some tradeoffs with lower specificity. Figure 3 shows that three
studies are outliers, and they represent studies of patients who were
previously screened for TB or studies in which much of the
population likely had previous TB screening (e.g., miners); this can
modify the performance characteristics of the screening rule.
The CFSW rule has sensitivity of 90.1% (95% CI 76.3%–
96.2%) and 67.1% (95% CI 41.7%–85.3%) among participants
selected from clinical and community settings, respectively.
Similarly the sensitivity of the rule among those who had not
been previously screened for TB was higher at 88.0% (95% CI
76.1%–94.4%) compared to those who had been screened for TB
at 40.5% (95% CI 16.6%–69.9%). At the 95% confidence level,
the sensitivity of this rule could not be statistically distinguished
from the sensitivity of the rule that substitutes haemoptysis for
current cough (HFSW, 75.7% sensitive [95% CI 53.9–89.2%]) or
the rule that drops night sweats (CFW, 74.0% sensitive [51.7–
88.3%]). All other rules had lower sensitivity.
Regression analysis of study-level predictors revealed that
studies in which TB screening was performed in clinical settings
had 4.5 times the odds for a true-positive screening result
compared to studies in which TB screening was performed in a
community setting (95% CI 1.0–19.5). Studies of participants who
had not previously been screened for TB had 10.8 times the odds
for a true-positive screen (95% CI 2.4–47.8) compared with studies
in which participants had previously been screened for TB.
Participants with CD4 cell count ,200 cells/ml had 6.4 times the
odds of a true-positive screen (95% CI 2.9–14.2). Statistically
significant predictors of true-negative results include prescreening,
geographic region, participant age $33 y, CD4 cell count ,200
cells/ml, and abnormal result on chest radiograph (Table 4).
Table 5 shows the negative predictive value and the numbers
needed to screen for the CFSW rule adjusted for individual- and
study-level covariates. In a setting with 5% TB prevalence among
people living with HIV, the rule has a negative predictive value of
98.3% (95% CI 97.5%–98.8%) for patients screened in a clinical
setting and 97.3% (95% CI 96.9%–97.7%) for patients screened in
a community setting. The numbers needed to screen at the same
prevalence of TB are 15 and 11 for clinical and community
setting, respectively. The negative predictive value was similar in
those having high ($200) and low (,200) CD4 count at 96.9%
(95% CI 95.1%–98.0%) and 98.9% (95% CI 97.5%–99.5%),
respectively (see also Table S3).
Four studies [20,23,24,26] consistently recorded information on
chest radiograph, allowing screening rules with this sign to be
evaluated using data from 2,805 participants The addition of
abnormal chest radiographic findings into the CFSW rule increases
the sensitivity to 90.6% (95% CI 66.7%–97.9%) with a specificity of
38.9% (95% CI 12.8%–73.3%), and a likelihood ratio negative of
0.242 (95% CI 0.102–0.571). Fifteen of the 23 rules included in our
analysis outperform the symptom-based CFSW rule when abnor-
mal chest radiographic findings are added (Table S4).
On the basis of our meta-analysis findings and incorporating
current WHO recommendations on provision of IPT, we
developed a simple TB screening algorithm for public health
programmes to screen people living with HIV, and, depending on
the outcome of screening, to either provide IPT or evaluate
patients further for TB or other diseases (Figure 4).
Discussion
We found that the absence of all of current cough, fever, night
sweats, and weight loss can identify a subset of people living with
Table 4. Association of study-level and individual-level
predictors with the diagnostic performance of CFSW rule.
Predictors
Sensitivity
(95% CI)
Specificity
(95% CI)
Study level
Setting Community 1.0
Clinical 4.45
(1.02, 19.46)a
0.25
(0.06–1.01)
Miners 0.25
(0.02–2.51)
4.07
(0.44–37.68)
Screening Prescreened
for TB
1.0
Not screened
for TB
10.82
(2.45–47.78)a
0.08
(0.06–0.12)a
Culture medium Solid 1.0
Liquid 3.41
(0.57–20.30)
0.33
(0.06–1.97)
Region Sub-Saharan Africa 1.0
Southeast Asia 4.03
(0.65–24.84)
0.20
(0.04–1.00)a
Individual level
Ageb ,33 y 1.0
$33 y 1.43
(0.81–2.52)
0.74
(0.66–0.84)a
Gender Female 1.0
Male 1.26
(0.71–2.24)
1.04
(0.93–1.16)
CD4 cell countc $200 cells/ml 1.0
,200 cells/ml 6.38
(2.87–14.17)a
0.46
(0.38–0.57)a
Abnormal chest
radiographd
No 1.0
Yes 1.36
(0.68–2.73)
0.41
(0.30–0.57)a
Values in each cell indicate the odds ratio for sensitivity or specificity compared
with a referent group.
ap-value ,0.05 for null hypothesis that odds ratio = 1.
bExcludes Shah et al. [24].
cIncludes only studies Cain et al. [20], Shah et al. [24], Lawn et al. [26], and
Chheng et al. [29].
dIncludes only studies Cain et al. [20], Lewis et al. [23], Shah et al. [24], and Lawn
et al. [25].
doi:10.1371/journal.pmed.1000391.t004
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HIV who have low probability of having TB disease. This
screening rule was superior over other candidate rules in eight of
the nine studies included and had an overall favourable
performance over competing rules in the hierarchical summary
relative operating characteristic (HSROC) analysis. We also
demonstrated that the negative predictive value of the rule was
high across a range of TB disease prevalence estimates and across
different population subsets, including those with low and high
CD4 count, and those drawn from clinical and community settings
and South African miners. We believe that these screening
questions are likely to be acceptable to practitioners, because they
are symptoms classically associated with TB disease.
Underdiagnosis and delayed diagnosis of TB contribute to
excess mortality among people living with HIV [17]. Similarly,
concerns about the ability to reliably rule out active TB before
initiating IPT have been a major barrier for wider use of this
intervention. In the absence of a rapid and effective TB diagnostic
tool available at the point-of-care, simple clinical algorithms must
be used to screen people living with HIV for TB, dividing them
into those in whom active TB is excluded and those who require
further evaluation. This meta-analysis synthesizes the best
available evidence for how to do this by relying on individual
patient data of culture-confirmed TB cases from people living with
HIV in the two regions of the world with the most severe burden
of the TB and HIV dual epidemic.
The major change to existing practice would be the replace-
ment of chronic cough with current cough as a screening question
and the addition of other symptoms to standard screening.
National TB programs have traditionally defined a TB ‘‘suspect’’
as someone with cough lasting greater than 2 or 3 wk, and
designed case-finding activities to investigate up to ten TB suspects
for every TB case detected [36]. However, studies included in this
analysis have shown that chronic cough is highly insensitive for TB
disease in people living with HIV; using this symptom as a
screening rule would miss cases and contribute to diagnostic delays
[16,20]. Using the combination of symptoms that we propose, in a
population of people living with HIV with a 5% TB prevalence
(excluding miners), requires the investigation of 13 extra patients
for every TB case detected, a ratio of TB suspects to a TB case not
much different from what national TB control programmes target
in the general population.
There has been ongoing debate about the importance of chest
radiography in screening people living with HIV for IPT eligibility
[37,38]. Our analysis showed that the addition of abnormal chest
radiography findings into the screening rule of CFSW increases
the sensitivity of the rule by 11.7% (90.6% versus 78.9%) with a
reduction of specificity by 10.7% (49.6% versus 38.9%). However,
for example at a 5% TB prevalence rate among people living with
HIV, augmenting the CFSW rule with abnormal chest radio-
graphic findings increases the negative predictive value by a
margin of only 1% (98.7% versus 97.8%), albeit with the same
number of cases needed to be screened. On the other hand, the
addition of abnormal chest radiographic findings to the rule at TB
prevalence of 20% among people living with HIV increases the
negative predictive value by almost 4% (94.3% versus 90.4%)
without additional cases needed to be screened. It is also worth
noting that the CFSW screening rule has higher sensitivity among
those who presented into a clinical setting (90%) and among those
who have not been previously screened for TB (88%).
Our findings show that the utility of the proposed symptom-
based screening rule have excellent performance in most settings
with TB and HIV burden. However, the negative predictive value
Table 5. Negative predictive value (NPV) and number needed to screen (NNS) using rule CFSW in a hypothetical population of
1,000 people living with HIV stratified by study and individual level predictors.
Participants 1% TB Prevalence 5% TB Prevalence 10% TB Prevalence 20% TB Prevalence
NPV 95% CI NNS NPV 95% CI NNS NPV 95% CI NNS NPV 95% CI NNS
All study participants 99.6 (99.5–99.6) 62 97.7 (97.4–98.0) 12 95.3 (94.6–95.9) 6 90.0 (88.6–91.3) 3
All study participants excluding miners 99.6 (99.5–99.7) 67 97.9 (97.5–98.2) 13 95.6 (94.8–96.3) 7 90.6 (89.0–92.1) 3
Setting Clinical 99.7 (99.5–99.8) 78 98.3 (97.5–98.8) 15 96.4 (94.8–97.5) 8 92.3 (89.0–94.6) 4
Community 99.5 (99.4–99.5) 55 97.3 (96.9–97.7) 11 94.5 (93.7–95.2) 5 88.5 (86.9–89.9) 3
Miners 99.2 (98.7–99.5) 38 96.1 (93.8–97.6) 8 92.2 (87.8–95.1) 4 84.0 (76.1–89.6) 2
Screening Nonscreened for TB 99.6 (99.5–99.7) 77 98.1 (97.5–98.5) 15 96.0 (94.9–96.9) 7 91.5 (89.2–93.3) 4
Prescreened for TB 99.3 (99.3–99.3) 36 96.5 (96.2–96.7) 7 92.8 (92.4–93.2) 4 85.1 (84.3–86.0) 2
Culture medium Liquid 99.6 (99.3–99.8) 75 98.2 (96.7–99.0) 15 96.2 (93.2–98.0) 7 91.9 (85.9–95.5) 3
Solid 99.5 (99.4–99.5) 57 97.3 (97.0–97.7) 11 94.6 (93.8–95.2) 6 88.5 (87.1–89.8) 3
Geography Southeast Asia 99.6 (99.2–99.8) 81 98,0 (95.9–99.0) 16 95,9 (91.6–98.0) 8 91.2 (83.0–95.6) 4
Sub-Saharan Africa 99.5 (99.4–99.6) 52 97.4 (97.1–97.8) 10 94.8 (94.0–95.4) 5 88.9 (87.5–90.2) 3
Age $33 y 99.6 (99.5–99.7) 63 97.8 (97.2–98.2) 12 95.4 (94.3–96.4) 6 90.3 (88.0–92.1) 3
,33 y 99.5 (99.4–99.6) 59 97.5 (97.0–97.9) 12 94.8 (94.0–95.6) 6 89.1 (87.4–90.6) 3
Gender Male 99.5 (99.4–99.6) 64 97.5 (97.2–97.9) 13 95.0 (94.2–95.6) 6 89.3 (87.8–90.6) 3
Female 99.6 (99.5–99.7) 60 98.0 (97.5–98.4) 12 95.8 (94.9,96.6) 6 91.0 (89.2–92.6) 3
CD4 cell count $200 cells/ml 99.4 (99.0–99.6) 80 96.9 (95.1–98.0) 16 93.6 (90.2–95.9) 8 86.7 (80.4–91.2) 4
,200 cells/ml 99.8 (99.5–99.9) 81 98.9 (97.5–99.5) 16 97.8 (94.8–99.1) 8 95.1 (89.1–97.9) 4
Abnormal chest
radiograph
Yes 99.4 (99.0–99.6) 83 97.0 (95.2–98.2) 16 93.9 (90.3–96.2) 8 87.2 (80.6–91.8) 4
No 99.5 (99.3–99.7) 61 97.7 (96.7–98.4) 12 95.2 (93.2–96.7) 6 89.9 (85.9–92.9) 3
doi:10.1371/journal.pmed.1000391.t005
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will fall in those settings with higher TB prevalence when symptom
screening alone is used, as it depends on prevalence of disease. In
particular settings (e.g., antiretroviral clinics with a very high TB
burden [39]), consideration must be given to use of an algorithm
that contains chest radiography, or even adding additional
sensitive investigations (e.g., culture) while screening people living
with HIV for TB [30,40]. People living with HIV and receiving
IPT should also be regularly screened for TB during their visit to a
health facility or contact with health care provider so as to
promptly detect active TB, if it develops. Programme managers
need to weigh the financial, technical, and logistic difficulties, and
patient cost and inconvenience associated with performing chest
radiography or other additional sensitive investigations on all
people living with HIV as part of a screening program compared
with an approach that relies only on symptomatic screening.
When interpreting our results, one must bear in mind that only
a few variables were common to all studies included in the meta-
analysis. It is possible that the addition of one or more symptoms
not included in our list of common symptoms could have
improved the performance of our proposed screening rule.
However, at least one study included in our meta-analysis
explored over 80 million combinations of about 100 signs and
symptoms and found a symptom combination (cough and fever of
any duration and night sweats for 3 weeks or longer), which was
similar to the one we propose as the best performing one [20].
Furthermore, questions were not asked in a uniform manner
across all studies, and the reporting of symptoms can be highly
dependent on factors such as the quality of the interview and
interviewer, the circumstances under which questions are asked,
and the social and cultural factors that shape individual
perceptions of symptoms and disease [41]. We reviewed all
questions carefully with principal investigators and data managers
to ensure accurate mapping of differently phrased questions to
common variables. Our study relied on patients drawn from
multiple countries and multiple settings, and the variation in the
performance of the proposed screening rule across these different
settings suggests that variation in patient self-report of symptoms is
unlikely to have major impact, at least at the population level. In
some studies, only one sputum specimen was collected for culture,
while multiple cultures are required to maximize sensitivity. Some
Figure 4. Algorithm for TB screening in person living with HIV in HIV prevalent and resource-constrained settings. * Every person
living with HIV needs to be evaluated for ART eligibility, and all settings providing care should reduce TB transmission through proper measures.
** Chest radiography is not required to classify patients into the TB and not-TB groups, but can be done, if available, to increase the sensitivity of
screening. *** Assess for contraindications, including active hepatitis (acute or chronic), regular and heavy alcohol consumption, and symptoms of
peripheral neuropathy, is required prior to initiating IPT. Past history of TB is not a contraindication for starting IPT. Tuberculin skin test may be
performed as part of eligibility screening in some settings. **** Investigations for TB should be done in accordance with existing national guidelines.
doi:10.1371/journal.pmed.1000391.g004
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patients with TB may have been incorrectly classified as not
having TB. Extrapulmonary TB is an important cause of
morbidity and mortality in people living with HIV, but most
studies included in the meta-analysis focused on screening for
pulmonary TB. Young children were not included in the studies.
We did not specifically look into the role of tuberculin skin test in
the proposed screening rule. Ideally, the utility of the algorithm we
propose, based on the screening rule from our meta-analysis,
should be studied prospectively using a standardized protocol in
multiple diverse sites; this is particularly important as the studies
included in our analysis came from only two geographical regions
of the world. Similarly, because of the time required for the data
aggregation, statistical analysis, manuscript preparation, and
publication, there was one potentially eligible study that was not
included in our analysis [30]. We believe that the exclusion of this
single study from South Africa, a country from which we have
included similar studies already, will not affect the interpretation of
our data and conclusions. In the future, as more studies are
reported, particularly from other regions, it will be important to
repeat the meta-analysis.
Greatly improving TB screening, diagnosis, and treatment in
people living with HIV will require deployment of a rapid,
accurate, point-of-care TB diagnostic test. In the absence of such a
test, we believe that a standardized algorithm employing
symptoms, as we propose here, can improve the diagnosis and
treatment of TB for people living with HIV, and by doing so
would save many lives. Reliable exclusion of TB disease will
facilitate safer initiation of antiretroviral therapy and will allow for
broader use of IPT, which can substantially reduce TB incidence.
Earlier and accurate HIV and TB screening and treatment may
also help identify infectious cases earlier, thereby reducing both
HIV and TB transmission. Evidence-based and internationally
recommended guidelines should be used to expedite the diagnosis
and treatment of TB in people living with HIV [42].
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Editors’ Summary
Background. In 2009, 1.7 million people died from
tuberculosis (TB)—equating to 4,700 deaths a day—
including 380,000 people living with HIV. TB remains the
most common cause of death in people living with HIV and
compared to people without HIV, people living with HIV are
more than 20 times more likely to develop TB. Furthermore,
TB infection may occur at any stage of HIV disease and is
often the initial presentation of underlying HIV infection.
Without antiretroviral treatment, up to 50% of people living
with HIV who are diagnosed with TB die during the 6–8
months of TB treatment.
Although antiretroviral treatment can reduce the incidence
of TB both at the individual and population level, people
living with HIV on antiretroviral treatment still have higher TB
incidence rates and a higher risk of dying from TB. Therefore,
the World Health Organization recommends regular screen-
ing for active TB disease in all people living with HIV, so
those identified as having active TB disease can be provided
with appropriate treatment, and isoniazid preventive therapy
(to help mitigate TB morbidity, mortality, and transmission)
can be given to vulnerable individuals who do not yet have
active TB.
Why Was This Study Done? There is currently no
internationally accepted evidence-based tool to screen for
TB in people living with HIV—a serious gap given that the
presenting signs and symptoms of TB in people living with
HIV are different from those in people without HIV.
Therefore, the researchers aimed to develop a simple,
standardized TB screening rule for resource-constrained
settings, on the basis of the best available evidence that
would adequately distinguish between people living with
HIV who are very unlikely to have TB from those who require
further investigation for TB disease.
What Did the Researchers Do and Find? The researchers
selected 12 studies that met their strict criteria, then asked
the authors of these studies for primary data so that they
could map individual-level data to identify five symptoms
common to most studies. Using a statistical model, the
researchers devised 23 screening rules derived from these
five symptoms and used meta-analysis methods (bivariate
random-effects meta-analysis) and the association of study-
level and individual-level correlates (hierarchical summary
relative operating characteristic curves) to evaluate the
sensitivity and specificity of each tool used in each
individual study.
The authors of the selected studies were able to provide data
for 29,523 participants, of whom 10,057 were people living
with HIV. The dataset included 9,626 people living with HIV
who had TB screening and sputum culture performed, of
which 8,148 individuals could be evaluated on the five
symptoms of interest from nine of 12 studies. TB disease was
diagnosed in 5.8% of people living with HIV and the best
performing rule was the presence of any one of the
following: current cough (any duration), fever, night sweats,
or weight loss. The overall sensitivity of the rule was 78.9%
and the specificity was 49.6%. However, the sensitivity of the
rule increased to 90.1% among participants selected from
clinical settings and to 88.0% among those who were not
previously screened for TB.
What Do These Findings Mean? The results of this study
suggest that in resource-constrained settings, the absence of
current cough, fever, night sweats, and weight loss (all
inclusive) can identify those people living with HIV who have
a low probability of having TB disease. Furthermore, any one
of these symptoms can be used in resource-constrained
settings to identify people living with HIV who are in need of
further diagnostic assessment for TB.
Despite the limitations of the methodology used in this
study, until there are evidence-based and internationally
recommended guidelines for the diagnosis and treatment of
TB in people living with HIV, use of the algorithm developed
and presented in this study could result in earlier TB
diagnosis and treatment for people living with HIV and
could help to substantially scale-up isoniazid preventive
therapy.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1000391.
N The World Health Organization has information about TB
in people living with HIV
N The US Centers for Disease Control and Prevention also
provide information about TB and HIV coinfection
N The World Health Organization also has information about
isoniazid preventative therapy
N The Stop TB Partnership’s TB/HIV Working Group provide
information about TB and HIV co-infection
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